Could a simple pill replace daily shots for clot prevention after cancer surgery?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must: * Provide signed and dated informed consent. * Be willing and able to comply with study procedures and follow-up. * Be 18-89 years old (male or female). * Have a negative pregnancy test within 24 hours before surgery (if woman of childbearing potential). * Have biopsy-proven head and neck cancer, or a suspected cancer awaiting tissue diagnosis (can be confirmed by frozen section at surgery). * Be scheduled for major inpatient or outpatient oncologic head and neck surgery (defined as \>45 minutes operative time). * Be an appropriate surgical candidate (adequate performance status). Eligible diagnoses include (not limited to): * Squamous cell carcinoma of oral cavity, hypopharynx, larynx, nasal cavity * Malignancies from major salivary glands * Non-melanoma skin cancers (squamous cell, basal cell, Merkel cell carcinoma) * Unknown primary tumors of head and neck Exclusion Criteria: Participants cannot: * Lack a tissue diagnosis of head and neck cancer during the study period. * Have one of these conditions instead of eligible cancer: Benign disease; Primary thyroid cancer (lower VTE risk); Lymphoma (not primarily surgical); or Melanoma * Fail to undergo definitive head and neck oncologic surgery (e.g., only diagnostic biopsy). * Have surgery limited to tissue diagnosis only (e.g., direct laryngoscopy, excisional lymph node biopsy). * Be unable (patient or caregiver) to administer the study drug. * Have a positive pregnancy test on the day of surgery. * Have a known history of prior DVT or PE (since extended anticoagulation would be indicated). * Have hereditary or acquired bleeding/clotting disorders. * Have severe renal impairment (CrCl \<30 mL/min). * Have conditions that, in the investigator's judgment, make study participation unsafe or confound results.